ManNAc to be Studied as Potential Treatment of Hereditary Inclusion Body Myopathy (HIBM) and Various Nephropathies Associated with Hyposialylation New York, NY – July 17, 2015 – Fortress Biotech, Inc. (NASDAQ: FBIO) announced that its subsidiary, Altamira Bio, acquired from New Zealand Pharmaceuticals Ltd (NZP), a license from the National Institutes of Health (NIH) and […]MORE >>
a majority-owned subsidiary of Fortress Biotech, Inc., is a development stage company focused on the clinical development and commercialization of therapies for orphan disorders.
We are currently developing N-acetyl-D-mannosamine (ManNAc) for the potential treatment of GNE myopathy and primary podocyte (glomerular) disorders in collaboration with NIH researchers.
- 2 Gansevoort Street, 9th Floor
- New York, NY 10014